Affordable Access

Fibrinolytic agents in the treatment of thrombotic disorders

Authors
Journal
Seminars in Oncology
0093-7754
Publisher
Elsevier - WB Saunders
Publication Date
Disciplines
  • Biology
  • Medicine

Abstract

Abstract The oncology patient is often at increased risk of bleeding when thrombolytics are administered. Fortunately, the factors placing the patient at risk are easily identified and include intracranial disease, vascular defects produced by surgery, instrumentation or tumor invasion, underlying coagulopathy, and severe thrombocytopenia. Unfortunately, new clot-specific agents have not eliminated the problem of undesirable bleeding; in fact, they may cause more bleeding by more efficiently dissolving both pathological thrombi and hemostatic plugs. The development of a means of delivering thrombolytics solely to the target clot is desirable and should be performed when possible. Despite the need for caution, thrombolytics are remarkably effective in treating both venous and arterial thrombi, and it is a disservice to the patient not to carefully consider their use.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Role of fibrinolytic agents in thrombotic diseases...

on Journal of the American Medica... May 21, 1960

Role of thrombotic and fibrinolytic disorders in o...

on Clinical Orthopaedics and Rela... December 2003

Role of thrombotic and fibrinolytic disorders in t...

on Clinical Orthopaedics and Rela... June 2002
More articles like this..